CONCLUSIONS: Ultrastaging may be safely omitted in patients with low-grade endometrioid endometrial cancer without myometrial invasion. No other subgroups with a risk of nodal metastasis of less than 1% have been identified....
Read more
Published on: 2024-03-21
Source:
Colombo Nicoletta
CONCLUSION: The SeqOne assay offers a clinically validated approach to detect HRD....
Read more
Published on: 2024-03-12
Source:
Colombo Nicoletta
No abstract...
Read more
Published on: 2024-03-07
Source:
Colombo Nicoletta
CONCLUSIONS: The incorporation of immunotherapy into the initial treatment for advanced and metastatic endometrial cancer brings about a substantial improvement in oncologic outcomes, especially within the MMRd/MSI-H subset. This specific subgroup is currently a focal point of investigation for evaluating the potential of chemotherapy-free regimens. Ongoing exploratory analyses aim to...
Read more
Published on: 2024-03-02
Source:
Colombo Nicoletta
CONCLUSION: Trabectedin did not improve median OS and showed a worse safety profile in comparison with physician's choice control chemotherapy....
Read more
Published on: 2024-02-05
Source:
Colombo Nicoletta
The European Society of Gynaecological Oncology, the European Society for Medical Oncology (ESMO) and the European Society of Pathology held a consensus conference (CC) on ovarian cancer on 15-16 June 2022 in Valencia, Spain. The CC panel included 44 experts in the management of ovarian cancer and pathology, an ESMO...
Read more
Published on: 2024-02-02
Source:
Colombo Nicoletta